Skip to main content

Table 3 Cytogenetics

From: Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

Cytogeneticsa IRD (N = 127) RD (N = 217) p1
t(4;14), n (%) n = 59 n = 86  
 Negative 53 (89.8%) 80 (93.0%) 0.548
 Positive 6 (10.2%) 6 (7.0%)
t(14;16), n (%) n = 52 n = 69  
 Negative 49 (94.2%) 66 (95.7%) 1.000
 Positive 3 (5.8%) 3 (4.3%)
del(17p13), n (%) n = 66 n = 91  
 Negative 58 (87.9%) 79 (86.8%) 1.000
 Positive 8 (12.1%) 12 (13.2%)
Cytogenetics - risk groupsb, n (%) n = 54 n = 77  
 Standard risk 39 (72.2%) 58 (75.3%) 0.691
 High risk 15 (27.8%) 19 (24.7%)
  1. a Only cytogenetics evaluated at diagnosis before treatment initiation included. Cytogenetics assessed in 69% of IRD patients (87/127) and 49% of RD patients (106/217) but most patients did not have all required parameters assessed. The table contains only the three major risk aberrations
  2. b “standard risk” = negative t(4;14) and t(14;16) and del(17p13); “high risk” = positive at least one of these aberrations
  3. 1 p-value of Fisher’s exact test for categorical variables